The rate of obesity in adolescents continues to rise. Currently, there is only one drug approved for the management of obesity in adolescents; however the drug is not suitable for everyone. There is a need for more options to help obese adolescents lose weight.
The NN8022-4180 research study will assess the safety and effectiveness of a study drug (Liraglutide) for use in the management of obesity in adolescents.
About the StudyThe study drug is approved by the U.S Food and Drug Administration for adults as a treatment option for weight loss. Researchers at Pennington Biomedical will assess the safety and effectiveness of the same drug in an adolescent population.
- 1 screening visit
- Up to 30 study visits to the Pennington Biomedical clinic over 82 weeks
- Health measurements (blood pressure, pulse, height, weight, etc.)
- Physical examination
- ECG test to determine heart health
- Blood tests
Number of Visits:
- Be 12 – 17 years old
- Have a BMI of 26 or above calculate your BMI
To qualify for this research study, participants should:
Study DurationParticipation in this research study will last approximately 1.5 years.
CompensationCompensation of up to $980 is offered for completion of this study.
Study ContactParents: To see if your 12-17 year old qualifies for this research study, you or a guardian must complete the online screening form below on his or her behalf. You may also call 225-763-3000 or email firstname.lastname@example.org.
If you think you may be eligible, please click the button below to screen online.GET STARTED
Please do not fill out this questionnaire for anyone other than yourself unless you are their legal guardian.
If you know someone who may be interested please direct them to the site or have them call us directly at 225-763-3000.